NCT06481371View on ClinicalTrials.gov

Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression

NANot yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

April 30, 2025

Conditions

Functional DyspepsiaDepression

Interventions

DRUG

zuojinwan

In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.

DRUG

Rabeprazole sodium enteric-coated tablets

For epigastric pain syndrome

DRUG

mosapride citrate

Postprandial discomfort syndrome

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT06481371 - Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression | Biotech Hunter | Biotech Hunter